-+ 0.00%
-+ 0.00%
-+ 0.00%

NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA

Benzinga·08/12/2026 12:03:42
Listen to the news

— Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047)

— Median overall survival of 26.09 months; 86.7% of patients alive at six months

— Five of 24 patients remain on treatment, with one partial response ongoing beyond 114 days

— No major toxicities reported across the cohort; adverse events predominantly low-grade

— Company to host investor conference call and webcast today at 8:30 a.m. Eastern Time